Investor Webinar

RNS Number : 4946I
Aptamer Group PLC
05 December 2022
 

05 December 2022

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

 Investor Webinar

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces that Dr Arron Tolley, Chief Executive Officer, David Bunka, Chief Technical Officer and Jenny Cutler, Interim Chief Financial Officer, will be presenting a live ShareSoc webinar on 6 December 5:00pm GMT.

 

The event will provide an opportunity for investors to learn more about the Company, its technology and progress made since IPO in December 2021. No new information will be disclosed during the event.

 

Further details of the event, along with a registration form, are available here:

https://www.sharesoc.org/events/sharesoc-webinar-with-aptamer-group-apta06-december-2022/

 

 

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Arron Tolley    +44 (0) 1904 217 404

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone                         +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFSEFALFIIF

Companies

Aptamer Group (APTA)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today